OVERVIEW

Real World, Case-Based Approaches to Optimizing Management of Gastrointestinal Neuroendocrine Tumors (NETs) is organized by CMEducation Resources, LLC. This CME Conference has been approved for a maximum of 2.50 AMA PRA Category 1 Credits.

Release date
July 11, 2017
Expiration date
July 11, 2019

Course Overview :
In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of gastrointestinal neuroendocrine tumors (NETs).

Conference Objectives are :
Upon completion of this activity, participants will be able to:
• Detail the epidemiology, burden, and clinical challenges associated with detecting, diagnosing and classifying gastroenteropancreatic neuroendocrine tumors (GEP- NETs);
• Classify GEP- NETs, into WHO- generated categories of: (a) well- differentiated NETs; and (2) poorly- differentiated neuroendocrine carcinomas (NECs) of the small- or large- cell type; and explain how further classification into functional and non- functional, and origin of the tumor, can impact management and treatment choices;
• Apply clinical practice guidelines for GEP- NETs from the European Society for Medical Oncology (ESMO), from NCCN, and other expert consensus panels, and therefore, become more clinically proficient at utilizing these evidence- based guidelines to the from lines of GI oncology practice;
• Determine which patients with metastatic GEP- NET are appropriate for the use of surgical interventions (resection), medical therapy, systemic chemotherapy, and peptide receptor- targeted radiotherapy, based on presentation, symptoms, tumor types and stage, clinical profiles, extent of disease, biomarkers, and other factors;
• Deploy emerging pharmacologic treatments for patients with GEP- NETs, including somatostatin analogs (SSAs), radiolabeled SSAs, cytotoxic drugs, angiogenesis inhibitors, and mammalian target of rapamycin (mTOR) inhibitors in patients with metastatic GEP- NETs.

Additional details will be posted as soon as they are available.